Notably, patients with diabetes with AD-related cognitive impairment using DPP-4 inhibitors exhibit a lesser amyloid burden and slower cognitive decline compared to patients without diabetes or patients with diabetes taking other glucose-lowering medications [82]. Here, DPP4 is linked to Cognitive impairment.